In vitro asexual blood stage cultures treated with the tested compound showed dose-dependent growth inhibition. In MDA-MB-231 cells, treatment consistently reduced BRCA1 protein levels, as assessed by Western blots with quantitation. In parental IGR-CaP1 cells, treatment at 100 nM was associated with an 83% decrease in the ability to form colonies. Immature gametocytes in in vitro cultures were treated with the study compound and showed dose-dependent growth inhibition. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Dose-dependent growth inhibition in asexual blood stage cultures
Cell-based study · Asexual blood stage (ABS, PfNF54) [1]
In vitro asexual blood stage cultures treated with the tested compound showed dose-dependent growth inhibition.
Literature-Reported Treatment Conditions
- Method
- in vitro cultures
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: CHIR-124
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r1)
dose-dependent growth inhibition: dose-dependent growth inhibition — Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r1)
Consistent BRCA1 Protein Downregulation
Cell-based study · MDA-MB-231 cells [2]
In MDA-MB-231 cells, treatment consistently reduced BRCA1 protein levels, as assessed by Western blots with quantitation.
Literature-Reported Treatment Conditions
- Reported limits
- Not stated in the sentences used: dose, route, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: CHIR-124
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Candidate compounds downregulate breast cancer susceptibility gene protein expression in MDA-MB-231 cells (S110, S111); Figure 7 legend (S328)
BRCA1 Western blots with quantitation: BRCA1 Western blots with quantitation — Results > Candidate compounds downregulate breast cancer susceptibility gene protein expression in MDA-MB-231 cells (S111); Figure 7 legend (S328)
Reduced Colony Formation in Parental IGR-CaP1 Cells
Cell-based study · parental IGR-CaP1 cells [3]
In parental IGR-CaP1 cells, treatment at 100 nM was associated with an 83% decrease in the ability to form colonies.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 nM
- Exposure duration
- Eight to 10 days later
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route, control.
Methods and source locations
Compound reported in the paper: CHIR-124
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESULTS > Targeting the CDC25C-interacting kinase CHEK1 to overcome Docetaxel resistance (S54, S60); MATERIALS AND METHODS > Cell culture, selection of Docetaxel-resistant clones and reagents (S70); MATERIALS AND METHODS > Foci formation assays (S111, S112)
ability of cells to form colonies: ability of cells to form colonies — RESULTS > Targeting the CDC25C-interacting kinase CHEK1 to overcome Docetaxel resistance (S60)
Dose-dependent growth inhibition in immature gametocytes
Cell-based study · Immature gametocytes (PfNF54) [1]
Immature gametocytes in in vitro cultures were treated with the study compound and showed dose-dependent growth inhibition.
Literature-Reported Treatment Conditions
- Method
- in vitro cultures
- Reported limits
- Not stated in the sentences used: dose, schedule, vehicle, control.
Methods and source locations
Compound reported in the paper: CHIR-124
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r2)
dose-dependent growth inhibition: dose-dependent growth inhibition — Results > CHIR-124 Identified via Kinobead Assays with Multistage Antiplasmodial Activity (S10); 1 (T1.h1, T1.r2)